Vol 8, No 3 (2022)
Research paper
Published online: 2022-09-30
Page views 555
Article views/downloads 19
Get Citation

Connect on Social Media

Connect on Social Media

Patients' needs and expectations towards local treatment of psoriasis — a survey study

Katarzyna Myśliwiec-Czajka1, Witold Owczarek1
Forum Dermatologicum 2022;8(3):124-130.


Introduction: Psoriasis is a chronic, inflammatory skin disease , significantly reducing the quality of life of patients. Very important element of effective psoriasis therapy is to understand the patient’s needs and expectations regarding medical care and treatment. The aim of the study was to get to know the patients’ needs during medical appointments and their expectations regarding psoriasis drug, as well as to obtain information what factors could change the currently used topical medications.

Material and methods: The survey was conducted by 53 dermatologists in the period from July to September 2021. The study was realized by using the face-to-face interview method: each of the doctors interviewed three patients suffering from psoriasis using a questionnaire with single- and multiple-choice questions. 159 questionnaires were included in the study. The questions concerned: the localization of psoriasis lesions, the body surface affected by psoriasis, the needs and expectations regarding the psoriasis drug and the psoriasis-related dermatological visits, the acceptable monthly cost of therapy, openness to new, previously unused medications, factors that may lead to a change of currently used medications and experiences with the combination product containing calcipotriol and betamethasone dipropionate in the form of a foam.

Results: On the basis of the collected data, it was found that in the context of medical visits, patients mainly expect information on how to use the recommended drugs and knowledge about new available preparations. The key features of the drug for psoriasis for patients are that it provides longer time without changes on the skin and fast action (rapid disappearance of psoriasis lesions). The factors that would make patients to change their current treatment coincide with their expectations for a psoriasis drug — the new drug should give rapid results, provide longer periods with no changes on the skin and reduce the number of relapses. 85% of respondents declare openness to new drugs. For 29% of the surveyed patients, the acceptable monthly cost of therapy exceeds PLN 100, and for 34% — 150 PLN. The combination product containing calcipotriol and betamethasone dipropionate in the form of a foam is or has been used by 3 of the interviewed patients with psoriasis, 82% of whom believe that it has better therapeutic effects than other preparations.

Conclusions: The results of the survey show that the socioeconomic situation and patients' preferences regarding the forms of therapy used in their medical history should be taken into account. According to patients’ opinion, factors significantly influencing the choice of the drug, are the rapid clinical response and the possibility of prolonged remission. In the study group, over 60% of patients declare their readiness to pay more than 100 PLN per month for topical treatment of psoriasis. Proper physician-patient communication can help personalize local therapy, which should lead to improved adherence and clinical efficacy.

Article available in PDF format

Add to basket: 49.00 PLN

Aready have access?


  1. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017; 31(2): 205–212.
  2. Reich A, Adamski Z, Chodorowska G, et al. Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2. Dermatology Review. 2020; 107(2): 110–137.
  3. Augustin M, Holland B, Dartsch D, et al. Adherence in the treatment of psoriasis: a systematic review. Dermatology. 2011; 222(4): 363–374.
  4. Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011; 25 Suppl 4: 9–14.
  5. Richards HL, Fortune DG, Griffiths CEM. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol. 2006; 20(4): 370–379.
  6. Belinchón I, Rivera R, Blanch C, et al. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016; 10: 2357–2367.
  7. Hong CH, Papp KA, Lophaven KW, et al. Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study. J Eur Acad Dermatol Venereol. 2017; 31(11): 1876–1883.
  8. Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (dovobet/daivobet/taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol. 2006; 154(6): 1155–1160.
  9. Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017; 31(1): 119–126.
  10. Torbica A, Fattore G, Ayala F. Eliciting preferences to inform patient-centred policies: the case of psoriasis. Pharmacoeconomics. 2014; 32(2): 209–223.